Cargando…
Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer
BACKGROUND: High-grade serous ovarian cancers (HGSCs) display a high degree of complex genetic alterations. In this study, we identified germline and somatic genetic alterations in HGSC and their association with relapse-free and overall survival. Using a targeted capture of 557 genes involved in DN...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351177/ https://www.ncbi.nlm.nih.gov/pubmed/37460928 http://dx.doi.org/10.1186/s13048-023-01234-x |
_version_ | 1785074291925057536 |
---|---|
author | Adamson, A. W. Ding, Y. C. Steele, L. Leong, L. A. Morgan, R. Wakabayashi, M. T. Han, E. S. Dellinger, T. H. Lin, P. S. Hakim, A. A. Wilczynski, S. Warden, C. D. Tao, S. Bedell, V. Cristea, M. C. Neuhausen, S. L. |
author_facet | Adamson, A. W. Ding, Y. C. Steele, L. Leong, L. A. Morgan, R. Wakabayashi, M. T. Han, E. S. Dellinger, T. H. Lin, P. S. Hakim, A. A. Wilczynski, S. Warden, C. D. Tao, S. Bedell, V. Cristea, M. C. Neuhausen, S. L. |
author_sort | Adamson, A. W. |
collection | PubMed |
description | BACKGROUND: High-grade serous ovarian cancers (HGSCs) display a high degree of complex genetic alterations. In this study, we identified germline and somatic genetic alterations in HGSC and their association with relapse-free and overall survival. Using a targeted capture of 557 genes involved in DNA damage response and PI3K/AKT/mTOR pathways, we conducted next-generation sequencing of DNA from matched blood and tumor tissue from 71 HGSC participants. In addition, we performed the OncoScan assay on tumor DNA from 61 participants to examine somatic copy number alterations (SCNA). RESULTS: Approximately one-third of tumors had loss-of-function (LOF) germline (18/71, 25.4%) or somatic (7/71, 9.9%) variants in the DNA homologous recombination repair pathway genes BRCA1, BRCA2, CHEK2, MRE11A, BLM, and PALB2. LOF germline variants also were identified in other Fanconi anemia genes and in MAPK and PI3K/AKT/mTOR pathway genes. Most tumors harbored somatic TP53 variants (65/71, 91.5%). Using the OncoScan assay on tumor DNA from 61 participants, we identified focal homozygous deletions in BRCA1, BRCA2, MAP2K4, PTEN, RB1, SLX4, STK11, CREBBP, and NF1. In total, 38% (27/71) of HGSC patients harbored pathogenic variants in DNA homologous recombination repair genes. For patients with multiple tissues from the primary debulking or from multiple surgeries, the somatic mutations were maintained with few newly acquired point mutations suggesting that tumor evolution was not through somatic mutations. There was a significant association of LOF variants in homologous recombination repair pathway genes and high-amplitude somatic copy number alterations. Using GISTIC analysis, we identified NOTCH3, ZNF536, and PIK3R2 in these regions that were significantly associated with an increase in cancer recurrence and a reduction in overall survival. CONCLUSIONS: From 71 patients with HGCS, we performed targeted germline and tumor sequencing and provided a comprehensive analysis of these 557 genes. We identified germline and somatic genetic alterations including somatic copy number alterations and analyzed their associations with relapse-free and overall survival. This single-site long-term follow-up study provides additional information on genetic alterations related to occurrence and outcome of HGSC. Our findings suggest that targeted treatments based on both variant and SCNA profile potentially could improve relapse-free and overall survival. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-023-01234-x. |
format | Online Article Text |
id | pubmed-10351177 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103511772023-07-18 Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer Adamson, A. W. Ding, Y. C. Steele, L. Leong, L. A. Morgan, R. Wakabayashi, M. T. Han, E. S. Dellinger, T. H. Lin, P. S. Hakim, A. A. Wilczynski, S. Warden, C. D. Tao, S. Bedell, V. Cristea, M. C. Neuhausen, S. L. J Ovarian Res Research BACKGROUND: High-grade serous ovarian cancers (HGSCs) display a high degree of complex genetic alterations. In this study, we identified germline and somatic genetic alterations in HGSC and their association with relapse-free and overall survival. Using a targeted capture of 557 genes involved in DNA damage response and PI3K/AKT/mTOR pathways, we conducted next-generation sequencing of DNA from matched blood and tumor tissue from 71 HGSC participants. In addition, we performed the OncoScan assay on tumor DNA from 61 participants to examine somatic copy number alterations (SCNA). RESULTS: Approximately one-third of tumors had loss-of-function (LOF) germline (18/71, 25.4%) or somatic (7/71, 9.9%) variants in the DNA homologous recombination repair pathway genes BRCA1, BRCA2, CHEK2, MRE11A, BLM, and PALB2. LOF germline variants also were identified in other Fanconi anemia genes and in MAPK and PI3K/AKT/mTOR pathway genes. Most tumors harbored somatic TP53 variants (65/71, 91.5%). Using the OncoScan assay on tumor DNA from 61 participants, we identified focal homozygous deletions in BRCA1, BRCA2, MAP2K4, PTEN, RB1, SLX4, STK11, CREBBP, and NF1. In total, 38% (27/71) of HGSC patients harbored pathogenic variants in DNA homologous recombination repair genes. For patients with multiple tissues from the primary debulking or from multiple surgeries, the somatic mutations were maintained with few newly acquired point mutations suggesting that tumor evolution was not through somatic mutations. There was a significant association of LOF variants in homologous recombination repair pathway genes and high-amplitude somatic copy number alterations. Using GISTIC analysis, we identified NOTCH3, ZNF536, and PIK3R2 in these regions that were significantly associated with an increase in cancer recurrence and a reduction in overall survival. CONCLUSIONS: From 71 patients with HGCS, we performed targeted germline and tumor sequencing and provided a comprehensive analysis of these 557 genes. We identified germline and somatic genetic alterations including somatic copy number alterations and analyzed their associations with relapse-free and overall survival. This single-site long-term follow-up study provides additional information on genetic alterations related to occurrence and outcome of HGSC. Our findings suggest that targeted treatments based on both variant and SCNA profile potentially could improve relapse-free and overall survival. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-023-01234-x. BioMed Central 2023-07-17 /pmc/articles/PMC10351177/ /pubmed/37460928 http://dx.doi.org/10.1186/s13048-023-01234-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Adamson, A. W. Ding, Y. C. Steele, L. Leong, L. A. Morgan, R. Wakabayashi, M. T. Han, E. S. Dellinger, T. H. Lin, P. S. Hakim, A. A. Wilczynski, S. Warden, C. D. Tao, S. Bedell, V. Cristea, M. C. Neuhausen, S. L. Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer |
title | Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer |
title_full | Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer |
title_fullStr | Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer |
title_full_unstemmed | Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer |
title_short | Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer |
title_sort | genomic analyses of germline and somatic variation in high-grade serous ovarian cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351177/ https://www.ncbi.nlm.nih.gov/pubmed/37460928 http://dx.doi.org/10.1186/s13048-023-01234-x |
work_keys_str_mv | AT adamsonaw genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer AT dingyc genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer AT steelel genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer AT leongla genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer AT morganr genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer AT wakabayashimt genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer AT hanes genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer AT dellingerth genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer AT linps genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer AT hakimaa genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer AT wilczynskis genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer AT wardencd genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer AT taos genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer AT bedellv genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer AT cristeamc genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer AT neuhausensl genomicanalysesofgermlineandsomaticvariationinhighgradeserousovariancancer |